Sunday, 12 November 2023
We proudly announce this ISPOR Short Course, which is offered in-person at the forthcoming ISPOR Europe 2023 conference in Copenhagen, Denmark.
The value of medical innovation depends on the perspective. Registration authorities (EMA, FDA) mainly consider the clinical value of the medical innovation, whereas national health authorities take a broader perspective by including clinical, economic criteria, and potential other criteria like equity and social values.
Interesting, we also include the perspective of the investor by applying economic valuation theory.
We include examples of orphan drugs and ATMPs which are most striking to illustrate the concepts, but we also include value assessment for more traditional innovative drugs in broad indications.
Our faculty: Marlene Gyldmark, Louis P. Garrison, Afschin Gandjour, Fred Sorenson and Mark Nuijten
Visit the ISPOR Europe 2023 Program page to register and learn more.